Oestrogen-receptor-α gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women

Authors: Ongphiphadhanakul1; Chanprasertyothin1; Payatikul1; Tung, S. Sae1; Piaseu1; Chailurkit1; Chansirikarn1; Puavilai1; Rajatanavin1

Source: Clinical Endocrinology, Volume 52, Number 5, May 2000 , pp. 581-585(5)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

OBJECTIVE

An oestrogen-receptor-α (ERα) gene polymorphism has been variably reported to be related to bone mass. To investigate whether this ERα gene polymorphism is associated with a functional difference, we assessed the response in bone mineral density (BMD) to oestrogen therapy in post-menopausal women in relation to ERα gene polymorphism. PATIENTS AND MEASUREMENTS

Subjects consisted of 124 Thai post-menopausal women. Sixty-three of the women were less than 6 years post-menopausal and 61 were more than 10 years post-menopausal with vertebral or femoral osteoporosis as defined by BMD T-score less than − 2.5. Subjects were randomly allocated to receive 0.3 mg (n = 67) or 0.625 mg (n = 57) of conjugated equine oestrogen (CEE). All subjects also took 5 mg medroxyprogesterone acetate. Vertebral and femoral neck BMD were measured at baseline and 1 year after treatment. Data were expressed as mean ± SEM. Capital P represents the absence of the restriction site while lower-case p indicates the presence of the restriction site. RESULTS

For subjects on 0.625 mg CEE, BMD at L2-4 increased significantly after 1 year in those with pp (n = 20) Pp (n = 29) and PP genotypes (n = 8) (P < 0.001). However, in subjects on 0.3 mg CEE, BMD at L2-4 increased significantly after 1 year in subjects with Pp (n = 34, + 7.6 ± 1.5%, P < 0.001) and PP genotypes (n = 13, + 6.9 ± 1.0%, P < 0.001), but not in those with pp genotype (n = 20, + 2.3 ± 2.1%, P = NS). After adjusting for age and years since menopause, the change in vertebral BMD was still lower in those without the P allele compared to those with the P allele (P < 0.05). Femoral BMD did not significantly change regardless of dose of CEE and genotype. CONCLUSIONS

We conclude that ERα gene polymorphism affects skeletal response to oestrogen in post-menopausal women. The effect of ERα gene polymorphism appears to be site-specific and does not relate to biochemical markers of bone turnover. Determination of ERα genotype may help identify post-menopausal women who will have more skeletal benefit from oestrogen therapy.

Document Type: Research article

DOI: 10.1046/j.1365-2265.2000.00979.x

Affiliations: 1: Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A